Sign in to view content

APX3330, an Oral Drug in Trial for DR and DME, Demonstrated a Favorable Safety and Tolerability Profile in Multiple Phase 1 and 2 Studies

Michael J Allingham, MD, PhD

Video
Published 2021

Related

Impact of PRAME Status on Gene Expression Profile to Predict Metastasis in Uveal Melanoma: Interim Analysis of the Collaborative Ocular Oncology Group Study Number 2 (COOG2)
Prithvi Mruthyunjaya, MD, MHS
Updates from the Field
2022
Race Representation in Diabetic Macular Edema Randomized Control Trials Compared to the United States Census Data
Abdul-Hadi Kaakour, MD, MS
Annual Meeting Talks
2021
Suprachoroidal Delivery of Small Molecule Suspensions: Pre-Clinical Results Correlate to Clinical Trial Outcomes
James C. Major, MD, PhD FACS FASRS
Annual Meeting Talks
2021

Category: Diabetic Retinopathy

See more